 |
1kits（10Vials）
| Quantity: | |
|---|---|
▎ 5-Amino-1MQ Structure
Source: PubChem | Molecular Formula: C10H11N2+ Molecular Weight: 159.21 g/mol CAS Number: 685079-15-6 PubChem CID：950107 Synonyms: 5-amino-1-methylquinolinium；PMX593N4N3 |
▎5-Amino-1MQ Research
What is the research background of 5-Amino-1MQ?
With the continuous rise in global incidence rates of metabolic diseases such as obesity and diabetes, identifying targets and drugs that can effectively regulate energy metabolism and improve metabolic disorders has become a significant research focus. Nicotinamide N-methyltransferase (NNMT), a key metabolic enzyme, plays a vital role in energy homeostasis. Its overexpression leads to issues like fat accumulation and insulin resistance, making NNMT regulation a potential therapeutic target for related diseases.
Against this backdrop, 5-Amino-1MQ has emerged as a specific NNMT inhibitor. By suppressing NNMT activity, it reduces abnormal nicotinamide methylation, restores intracellular NAD+ levels and normalizes related signaling pathways, thereby improving lipid metabolism and enhancing insulin sensitivity. 5-Amino-1-methylquinolinium has emerged as a key research target for exploring novel therapeutic strategies against metabolic disorders, spurring fundamental studies on its mechanisms.
What effects does 5-Amino-1-methylquinolinium exert on adipocyte metabolism?
Effects on Adipogenesis
Inhibition of Adipogenesis: Adipogenesis refers to the process where preadipocytes differentiate into mature adipocytes and accumulate lipids during adipocyte development. Research indicates that methylquinolinium scaffolds bearing primary amine substituents exhibit high permeability for both passive and active transmembrane transport, while their analogues demonstrate highly selective inhibitory activity against nicotinamide N-methyltransferase (NNMT) [1]. NNMT inhibitors suppress adipogenesis in adipocytes, leading to the hypothesis that 5-Amino-1-methylquinolinium, if possessing similar NNMT inhibitory activity, is highly likely to reduce adipogenesis by inhibiting NNMT. For example, in cultured adipocyte experiments, NNMT inhibitors decrease intracellular 1-methylnicotinamide (1-MNA) levels, increase intracellular nicotinamide adenine dinucleotide (NAD⁺) and S-(5'-adenosyl) -L-methionine (SAM), and inhibit adipogenesis in fat cells[1].
Influencing adipogenesis-related gene expression: Adipogenesis is regulated by a series of transcription factors and genes, such as peroxisome proliferator-activated receptor-gamma (PPAR-γ) and CCAAT/enhancer-binding protein (C/EBP). Methylquinoline derivatives inevitably influence lipogenesis by affecting the expression of these key genes.
Figure 1 Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.
Source: ScienceDirect[1]
Effects on Lipid Metabolism
Regulation of proteins involved in lipid synthesis and degradation: Lipid metabolism encompasses processes such as lipid synthesis, storage, and degradation. In studies of metabolic-associated fatty liver disease (MAFLD), Donglingcao modulates the activity of peroxisome proliferator-activated receptor -α (PPAR-α), sterol regulatory element-binding protein-1c (SREBP-1c), fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC). 5-Amino-1-methylquinolinium may influence lipid metabolism in adipocytes through a similar mechanism, namely by regulating the expression of these key proteins involved in lipid synthesis and degradation. For example, if 5-Amino-1-methylquinolinium can upregulate PPAR-α expression, it may promote fatty acid oxidation and reduce lipid accumulation within adipocytes. Conversely, if it affects the expression of SREBP-1c, FAS, and others, it may influence fatty acid synthesis processes.
Altering intracellular metabolite levels to influence lipid metabolism: Intracellular metabolite levels play a crucial regulatory role in lipid metabolism. As previously mentioned, NNMT inhibitors can modify intracellular levels of metabolites such as 1-MNA, NAD⁺, and SAM, thereby affecting adipocyte metabolism[1]. If 5-Amino-1-methylquinolinium produces similar effects on these metabolite levels, it would indirectly regulate lipid metabolism. As a crucial intracellular coenzyme involved in multiple metabolic pathways, alterations in NAD⁺ levels may influence lipid metabolism-related processes such as fatty acid oxidation and the tricarboxylic acid cycle.
Effects on Energy Metabolism
Effects on Mitochondrial Activity: Energy metabolism in adipocytes is closely linked to mitochondrial function. Studies indicate that under in vitro simulated static stretching conditions, mitochondrial activity in adipocytes increases, promoting lipogenesis and accelerating cellular metabolism[2]. Methylquinolinium compounds may alter mitochondrial activity by influencing mitochondrial-related metabolic pathways or protein expression. If 5-Amino-1-methylquinolinium inhibits certain key mitochondrial proteins or metabolic processes, it may reduce mitochondrial activity and decrease energy expenditure in adipocytes. Conversely, it may promote energy metabolism. For example, by affecting the activity of mitochondrial respiratory chain complexes, it could regulate ATP production, thereby influencing the energy state and metabolic direction of adipocytes.
Regulating adipocyte energy balance: Adipocytes not only store energy but also participate in energy balance regulation. The effects of 5-Amino-1-methylquinolinium on adipocyte metabolism may ultimately manifest in energy balance regulation. If it inhibits lipogenesis and promotes lipolysis, it may reduce energy storage and increase energy release in adipocytes. Conversely, if it promotes lipogenesis and inhibits lipolysis, it could lead to excessive energy accumulation within adipocytes, disrupting energy balance—a critical factor in the development of obesity and related metabolic disorders.
Effects on Adipocyte Endocrine Function
Influences adipokine secretion: As endocrine organs, adipocytes secrete multiple adipokines such as leptin and adiponectin, which play crucial regulatory roles in systemic metabolism [3]. Certain drugs or substances can influence adipocyte secretion of these adipokines. While no direct evidence exists regarding 5-Amino-1-methylquinolinium's effect on adipokine secretion, its overall impact on adipocyte metabolism suggests potential indirect regulation of adipokine secretion. If 5-Amino-1-methylquinolinium alters adipocyte energy status or lipid metabolism, it may feedback-regulate leptin secretion. As a signaling molecule reflecting fat stores, changes in leptin secretion influence appetite and energy metabolism.
Influencing Inflammatory Cytokine Secretion: The inflammatory state of adipose tissue is closely linked to adipocyte metabolism. Adipocytes can secrete various inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) (Michalczyk K). In obese states, increased adipose tissue inflammation leads to heightened secretion of these inflammatory factors, subsequently affecting systemic metabolism and insulin sensitivity. 5-Amino-1-methylquinolinium, if capable of regulating adipocyte metabolism, may alter cytokine secretion, thereby influencing the inflammatory microenvironment of adipose tissue and affecting obesity-related metabolic complications. Its potential to inhibit cytokine secretion could help mitigate insulin resistance and improve metabolic status.
About The Author
The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.
Scientific Journal Author
Harshini Neelakantan is a pharmaceutical scientist and research leader with extensive experience in preclinical drug development for metabolic, neurological, and musculoskeletal disorders. She currently serves as Executive Director of Research & Development at Ridgeline Therapeutics, focusing on the translation of small-molecule therapeutics from hit-to-lead validation toward clinical application. Her expertise spans in vivo pharmacology, disease modeling, and drug metabolism, and she previously worked at the University of Texas Medical Branch.Harshini Neelakantan is listed in the reference of citation [1].
